Exemestane in Post-Menopausal Women With NSCLC

  • STATUS
    Not Recruiting
  • participants needed
    29
  • sponsor
    Masonic Cancer Center, University of Minnesota
Updated on 28 May 2022
metastasis
neutrophil count
pembrolizumab
ROS1
EGFR
brain metastases
nivolumab
cancer chemotherapy
atezolizumab
lung carcinoma
secondary malignant neoplasm of liver
proto-oncogene tyrosine-protein kinase ros

Summary

This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).

Details
Condition Non-Small Cell Lung Cancer
Treatment exemestane
Clinical Study IdentifierNCT02666105
SponsorMasonic Cancer Center, University of Minnesota
Last Modified on28 May 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note